GlassScriptPhysician profile
Holly Chapman
NPI 1730678103
$2,619.92
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,571 · 2022: $492 · 2023: $148 · 2024: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.04 | 2021-2024 | |
| Lilly USA, LLC | $216.81 | 2021-2024 | Mounjaro |
| Amgen INC. | $214.94 | 2021-2024 | Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $208.06 | 2021-2024 | Trintellix |
| Medtronic, INC. | $197.94 | 2021-2024 | Ellipsys Vascular Access System |
| Amarin Pharma, INC. | $193.29 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $182.63 | 2021 | |
| Novo Nordisk INC | $166.97 | 2021-2022 | |
| Esperion Therapeutics, INC. | $100.25 | 2021-2024 | Nexletol |
| Corium, LLC | $89.97 | 2021-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $85.03 | 2022-2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $76.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $65.63 | 2021-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $64.28 | 2021 | |
| Adlon Therapeutics L.P. | $59.55 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.90 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.56 | 2021 | |
| Merck Sharp & Dohme LLC | $41.00 | 2021 | |
| Lundbeck LLC | $27.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.95 | 2021 | |
| Organogenesis INC. | $22.24 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.49 | 2021 | |
| Bausch Health US, LLC | $18.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.26 | 2022 | |
| Organon LLC | $16.34 | 2022 | |
| Currax Pharmaceuticals LLC | $15.71 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.97 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.79 | 2022 | |
| W. L. Gore & Associates, INC. | $14.55 | 2023 | Gore Viabahn Endoprosthesis |
| Bayer Healthcare Pharmaceuticals INC. | $14.48 | 2024 | |
| Ironshore Pharmaceuticals INC. | $13.37 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.08 | 2024 | Quviviq |
| Tris Pharma INC | $12.58 | 2021 | |
| Medicure Pharma INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.